Lisata Therapeutics公司于美国证券交易委员会（SEC）提交的文件中披露，其董事会正着手评估一系列战略选项。这些备选方案包括反向并购、资产出售等可能性。此举预示着这家生物制药企业或将迎来重大结构变革。
Lisata Therapeutics公司于美国证券交易委员会（SEC）提交的文件中披露，其董事会正着手评估一系列战略选项。这些备选方案包括反向并购、资产出售等可能性。此举预示着这家生物制药企业或将迎来重大结构变革。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.